Melamed Guy

CFO/COO Melamed Guy sold 10,400 shares of VRNS at $59.53 on 2025-08-22; stock now at $57.39, unprofitable company with recent pattern of well-timed sells.

Melamed Guy, CFO and COO, sold 10,400 shares at $59.53, reducing his VRNS holdings to 417,497 shares. The sale occurred near the 52-week high of $59.98 and the stock has since declined -4.3%, trading at $57.39. Across his prior five trades at VRNS, Melamed has demonstrated strong timing discipline: 3 of 3 prior measurable sales yielded negative 90-day returns (-12.0%, -13.2%, -20.2%), and his cross-ticker track record shows a 100.00% well-timed rate on 7 prior sells. The sale is noteworthy given Varonis' unprofitable status (full-year net income negative, latest quarter showing $-35.8M net income) despite +10.4% annual revenue growth, suggesting the CFO may be responding to margin pressures or profitability concerns.

CFO Guy Melamed sold 42,705 shares at $57.72; all 4 measurable prior VRNS sales were negative 90-day performers

Guy Melamed (CFO and COO) sold 42,705 shares at $57.72 on 2025-08-13, reducing holdings by 9.1% from 470.6K to 427.9K shares. His prior four sales at VRNS between February and November 2024 were all well-timed at the 90-day mark: two sales on 2024-11-13 returned -12.0% and -13.2% respectively, one on 2024-02-08 returned -20.2%, and another on 2024-02-08 returned -0.3% and -8.6% at 90 days. This pattern of consistent negative returns after his VRNS sales—all 4 of 4 prior sells well-timed—suggests an identifiable ability to exit before subsequent declines at this ticker specifically. The company remains unprofitable with net income of $-35.8M against $152.2M quarterly revenue, despite 10.4% annual revenue growth. The current stock price is $58.41, only 2.6% below the 52-week high, and has rallied +16.1% in the past 30 days and +26.1% in 90 days—making this sale occur near elevated valuations.

CFO Melamed Guy sold 51,889 shares of VRNS at $55.10 for $2,859,083.90; 5 prior same-ticker sells all well-timed at 90d mark.

Melamed Guy sold 51,889 shares (51.9K shares) at $55.10 on 2025-08-01, reducing his VRNS holdings by 9.9% from 522,491 to 470,602 shares. This sale is particularly notable given his prior trade history at this ticker: he has executed 5 previous sales at VRNS, and all 5 were well-timed (showing negative 90-day returns, with a perfect timing pattern of 5 of 5 at the 90-day mark). His cross-ticker track record also shows a 100.00% 90-day well-timed rate across 5 prior sells, with an average 90-day return of -13.0%, indicating consistent execution before subsequent declines. The company remains unprofitable (net income $-35,824,000.00 for the latest quarter) despite 10.4% annual revenue growth, which provides context for elevated insider selling activity by a senior financial executive.

CFO/COO Melamed Guy sold 91,345 shares ($4.9M) at $53.70 avg; stock now $51.08, down 14.8% from 52-week high.

Melamed Guy executed 2 separate sales totaling 91,345 shares for $4,905,444.08 at a blended average price of $53.70, reducing his holdings by 15.3%. The shares have since declined to $51.08, positioning this as a well-timed exit within the context of his prior trading activity at VRNS: 3 of 3 earlier sales at this ticker showed negative 90-day returns, establishing a consistent pattern of selling before declines. His cross-ticker track record shows a 100.00% well-timed rate across 3 prior sells with an average 90-day return of -7.8%. The broader context shows VRNS trading 14.8% below its 52-week high and the company running unprofitable ($-18,333,000.00 net income in the latest quarter), suggesting the CFO's recent sale aligns with deteriorating financial performance. This level of executive liquidation—reducing a significant portion of C-suite holdings while the stock faces headwinds—merits investor attention.